Nov 14, 2023 / 09:00AM GMT
Martin Olin BerGenBio ASA-CEO
Good morning. My name is Martin Olin. And with me today, I have Cristina Oliva, the Chief Medical Officer of BerGenBio. Today, we will provide you with an update on our business and our Q3 financial report. And we will provide you with some insight into what we consider to be a very novel approach to address a significant unmet medical need in non-small cell lung cancer.
I'll just remind the audience about the formalities and forward-looking statements.
So to recap, BerGenBio -- what we're doing -- it is known that AXL, a cell surface protein, plays a key role in the progression of cancer, including non-small cell lung cancer. And we are focused entirely on developing our lead compound, bemcentinib, for selective inhibition of AXL to delay chemoresistance and also potentiate immunotherapy in non-small cell lung cancer, two of the known pure prognostic factors in a large subset of non-small cell lung cancer patients that, today, doesn't respond very well to standard of care, which consists of chemotherapy and immune checkpoint inhibition.
We
Q3 2023 Bergenbio ASA Earnings Call Transcript
Nov 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers